Understanding FcRn Inhibition and Pathogenic IgG Reduction in MG

In ‘Understanding FcRn Inhibition and Pathogenic IgG Reduction in MG,’ our panel explores the physiologic role of the neonatal Fc receptor and the rationale for FcRn-targeted treatment in myasthenia gravis. Faculty explain how FcRn acts as an IgG salvage and recycling receptor, protecting IgG from lysosomal degradation and contributing to its relatively long circulating half-life. In MG, this same process preserves pathogenic IgG antibodies that contribute to neuromuscular junction dysfunction.

The experts describe how blocking FcRn prevents IgG from being recycled, directing both pathogenic and nonpathogenic IgG toward degradation and reducing the circulating antibody pool. This mechanism is characterized as a downstream intervention that targets existing pathogenic antibodies rather than their production. The panel draws a practical comparison with plasma exchange because both strategies reduce circulating antibodies, while noting that FcRn-targeted therapy provides a pharmacologic approach to achieving this effect.

Faculty then discuss the relatively rapid onset associated with FcRn inhibition and why this can be clinically meaningful for patients experiencing functionally important symptoms. They consider how comorbidities, symptom severity, and the suitability of corticosteroids may influence when an FcRn-targeted therapy is introduced. The experts also describe a potential bridging role for FcRn inhibition when a patient requires faster disease control while waiting for slower conventional immunosuppressive therapies to become effective.

Our next episode, ‘Differentiating FcRn-Targeted Therapies in MG Clinical Practice,’ will examine molecular, dosing, and administration differences across FcRn-targeted therapies and how these distinctions may influence individualized treatment selection.